OIG Advisory Opinion: 23-06

    Unfavorable

    Paying physician-linked labs for the technical component of commercial pathology tests

    Recorded opinion date:

    The commentary below transcribes Cabra's existing summary PDF. It preserves the original analysis, including its checklist and wording. The original PDF remains available below. Advisory opinions concern their particular facts and requestors; this commentary is not legal advice.

    What OIG Said

    Carving out Federal patients doesn’t fix a deal that still feels like paying for referral flow.

    ⚠OIG reviewed a proposal where a national anatomic pathology lab would buy only the technical component from other labs (including physician-owned labs) for commercially insured patients, then bill commercial payors for both technical + professional components.

    ⚠Even though the per-specimen technical fees were described as FMV and Federal program business was “carved out,” OIG said the payments still count as remuneration to referral sources who are positioned to send Medicare/Medicaid specimens.

    ⚠OIG emphasized its longstanding view that carve-outs are not dispositive, commercial payments can disguise inducement for Federal referrals when the same physicians control where all specimens go.

    ⚠The national lab admitted it could do the technical work in-house cheaper and more efficiently, yet would pay third- party labs anyway, and expected to gain Federal referrals as a result. OIG saw no commercially reasonable purpose other than buying steerage.

    Diligence Checklist

    What you need to be ready to show in diligence

    ✓Have a defensible FMV analysis for every payment stream, but understand FMV alone does not neutralize AKS intent risk.

    ✓Prove a commercially reasonable business rationale for outsourcing work you can do better/cheaper internally, document the “why,” not just the “price.”

    ✓Show the arrangement is operationally necessary and not a convenience payment to referral sources (scope, volume, and selection logic should make sense without Federal referral upside).

    ✓Avoid structures where commercial dollars flow to parties who also control Federal referrals unless the model can stand on its own economics.

    ✓Keep tight contracts: defined services, no side deals, and no strategic “share the work to win the network” narrative in emails or decks.

    If you’re paying referral-source entities for commercially carved-out work without a clear, efficiency-based business need, this is the profile OIG said will draw fire.

    Structure not diligence-ready?

    Cabra Consulting helps healthcare organizations make sure compensation and transaction structures are independently valued, clearly scoped, and defensible in diligence.

    Original PDF cover text

    UNFAVORABLE

    OIG WATCH 23-06

    Paying physician-linked labs for the technical component of commercial pathology tests

    Cabra commentary publication date is not recorded in the existing source. No publication or revision date has been inferred from this HTML conversion.

    Source documents

    Preparing document preview…

    Ready to Move Forward?

    Let's explore how we can support your goals